LIPID-BASED FORMULATIONS FOR ORAL ADMINISTRATION: OPPORTUNITIES FOR BIOAVAILABILITY ENHANCEMENT AND LIPOPROTEIN TARGETING OF LIPOPHILIC DRUGS

REFERENCES

• Shiau Y.-F. Mechanism of intestinal fat absorption. Am. J. Physiol. 1981; 240: G1–G9
   PubMed Web of Science ®Google Scholar
• Bisgaier C. L., Glickman R. M. Intestinal synthesis, secretion and transport of lipoproteins. Annu. Rev. Physiol. 1983; 45: 625–636
   PubMed Web of Science ®Google Scholar
• Thomson A. B.R., Keelan M., Garg M. L., Clandinin M. T. Intestinal aspects of lipid absorption: in review. Can. J. Physiol. Pharmacol. 1989; 67: 179–191
   PubMed Web of Science ®Google Scholar
• Tso P. Intestinal lipid absorption. Physiology of the Gastrointestinal Tract, L. R. Johnson, Chief. Raven Press, New York 1994; 1867–1908
   Google Scholar
• Carey M. C., Small D. M., Bliss C. M. Lipid digestion and absorption. Annu. Rev. Physiol. 1983; 45: 651–677
   PubMed Web of Science ®Google Scholar
• Staggers J. E., Hernell O., Stafford R. J., Carey M. C. Physical-chemical behaviour of dietary and biliary lipids during intestinal digestion and absorption. 1. Phase behaviour and aggregation states of model lipid systems patterned after aqueous duodenal contents of healthy adult human beings. Biochemistry 1990; 29: 2028–2040
   PubMed Web of Science ®Google Scholar
• Hernell O., Staggers J. E., Carey M. C. Physical-chemical behaviour of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings. Biochemistry 1990; 29: 2041–2056
   PubMed Web of Science ®Google Scholar
• Hoffman N. E. The relationship between uptake in vitro of oleic acid and micellar solubilization. Biochim. Biophys. Acta 1970; 196: 193–203
   PubMedGoogle Scholar
• Simmonds W. J. The role of micellar solubilisation in lipid absorption. Aust. J. Exp. Biol. Med. Sci. 1972; 50: 403–421
   PubMedGoogle Scholar
• Westergaard H., Dietschy J. M. The mechanism whereby bile acid micelles increase the rate of fatty acid and cholesterol uptake into the mucosal cell. J. Clin. Invest. 1976; 58: 97–108
   PubMed Web of Science ®Google Scholar
• Shiau Y.-F., Fernandez P., Jackson M. J., McMonagle S. Mechanisms maintaining alow pH microclimate in the intestine. Am. J. Physiol. 1985; 248: G608–619
   Google Scholar
• Shiau Y.-F. Mechanism of intestinal fatty acid uptake in the rat: the role of an acidic microclimate. J. Physiol. 1990; 421: 463–474
   PubMedGoogle Scholar
• Kiyasu J. Y., Bloom B., Chaikoff I. L. The portal transport of absorbed fatty acids. J. Biol. Chem. 1952; 199: 415–419
   PubMed Web of Science ®Google Scholar
• Spady D. K. Lipoproteins in biological fluids and compartments: synthesis interconversions and catabolism. Lipoproteins as Carriers of Pharmacological Agents, J. M. Shaw. Marcel Dekker, New York 1991; 1–44
   Google Scholar
• Fielding P. E., Fielding C. J. Dynamics of lipoprotein transport in the circulatory system. Biochemistry of Lipids Lipoproteins and Membranes, D. E. Vance, J. Vance. Elsevier, New York 1991; 427–459
   Google Scholar
• Hunt J. N., Knox M. T. A relation between the chain length of fatty acids and the slowing of gastric emptying. J. Physiol. 1968; 194: 327–336
   PubMed Web of Science ®Google Scholar
• Anderberg E. K., Lindmark T., Artursson P. Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route. Pharm. Res. 1993; 10: 857–864
   PubMed Web of Science ®Google Scholar
• Aungst B. J. Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J. Pharm. Sci. 1993; 82: 979–987
   PubMed Web of Science ®Google Scholar
• Swenson E. S., Milisen W. B., Curatolo W. Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility. Pharm. Res. 1994; 11: 1132–1142
   PubMed Web of Science ®Google Scholar
• Armstrong N. A., James K. C. Drug release from lipid based dosage forms. Part 2. Int. J. Pharmaceut. 1980; 6: 195–204
   Web of Science ®Google Scholar
• Humberstone A. J., Charman W. N. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv. Drug Deliv. Rev. 1997; 25: 103–128
   Web of Science ®Google Scholar
• Charman W. N., Porter C. J.H., Mithani S., Dressman J. B. Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J. Pharm. Sci. 1997; 86: 269–282
   PubMed Web of Science ®Google Scholar
• Chakrabarti S., Belpaire F. M. Bioavailability of phenytoin in lipid containing dosage forms in rats. J. Pharm. Pharmac. 1978; 30: 330–331
   PubMed Web of Science ®Google Scholar
• Hargrove J. T., Maxson W. S., Wentz A. C. Absorption of oral progesterone is influenced by vehicle and particle size. Am. J. Obstet. Gynecol. 1989; 161: 948–951
   PubMed Web of Science ®Google Scholar
• Abrams L. S., Weintraub H. S., Patrick J. E., McGuire J. L. Comparative bioavailability of a lipophilic steroid. J. Pharm. Sci. 1978; 67: 1287–1290
   PubMedGoogle Scholar
• Yamaoka Y., Roberts R. D., Stella V. J. Low-melting phenytoin prodrugs as alternative oral delivery modes for phenytoin: a model for other high-melting sparingly water-soluble drugs. J. Pharm. Sci. 1983; 72: 400–405
   PubMed Web of Science ®Google Scholar
• Stella V., Haslam J., Yata N., Okada H., Lindenbaum S., Higuchi T. Enhancement of bioavailability of a hydrophobic amine antimalarial by formulation with oleic acid in a soft gelatin capsule. J. Pharm. Sci. 1978; 67: 1375–1377
   PubMed Web of Science ®Google Scholar
• Tokumura T., Tsushima Y., Tatsuishi K., Kayano M., Machida Y., Nagai T. Enhancement of the oral bioavailability of cinnarizine in oleic acid in beagle dogs. J. Pharm. Sci. 1987; 76: 286–288
   PubMed Web of Science ®Google Scholar
• Yamahira Y., Noguchi T., Takenaka H., Maeda T. Biopharmaceutical studies of lipid containing oral dosage forms: relationship between drug absorption rate and digestibility of vehicles. Int. J. Pharmaceut. 1979; 3: 23–31
   Google Scholar
• Myers R. A., Stella V. J. Systemic bioavailability of penclomedine (NSC338720) from oil-in-water emulsions administered intraduodenally to rats. Int. J. Pharmaceut. 1992; 78: 217–226
   Web of Science ®Google Scholar
• Palin K. J., Wilson C. M. The effect of different oils on the absorption of probucol in the rat. J. Pharm. Pharmac. 1984; 36: 641–643
   PubMed Web of Science ®Google Scholar
• Carrigan P. J., Bates T. R. Biopharmaceutics of drugs administered in lipid-containing dosage forms I: GI absorption of griseofulvin from an oil-in-water emulsion in the rat. J. Pharm. Sci. 1973; 62: 1476–1479
   PubMed Web of Science ®Google Scholar
• Bates T. R., Carrigan P. J. Apparent absorption kinetics of micronized griseofulvin after its oral administration on single- and multiple-dose regimens to rats as a corn oil-in-water emulsion and aqueous suspension. J. Pharm. Sci. 1975; 64: 1475–1481
   PubMed Web of Science ®Google Scholar
• Charman W. N., Rogge M. C., Boddy A. W., Berger B. M. Effect of food and a monoglyceride emulsion formulation on danazol bioavailability. J. Clin. Pharmacol. 1993; 33: 381–386
   PubMed Web of Science ®Google Scholar
• Serajuddin A. T., Sheen P., Mufson D., Bernstein D. F., Augustine M. A. Physicochemical basis of increased bioavailability of a poorly water-soluble drug following oral administration as organic solutions. J. Pharm. Sci. 1988; 77: 325–329
   PubMed Web of Science ®Google Scholar
• Hauss D. J., Fogal S. E., Ficorilli J. V., Price C. A., Roy T., Jayaraj A. A., Keirns J. J. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water soluble LTB4 inhibitor. J. Pharm. Sci. 1988; 87: 164–169
   Google Scholar
• Kimura T., Fukui E., Kageyu A., Kurohara Y., Nakayama T., Morita Y., Shibusawa K., Ohsawa S., Takeda Y. Enhancement of oral bioavailability of d-a-tocopherol acetate by lecithin-dispersed aqueous preparations containing medium-chain triglyceridies in rats. Chem. Pharm. Bull. 1989; 37: 439–441
   PubMed Web of Science ®Google Scholar
• Groves M. J., de Galindez D. A. The self-emulsifying action of mixed surfactants in oil. Acta. Pharm. Suec. 1976; 13: 361–372
   PubMedGoogle Scholar
• Groves M. J., Mustafa R. M.A., Carless J. E. Phase studies of mixed phosphated surfactants n-hexane and water. J. Pharm. Pharmac. 1974; 26: 616–623
   PubMed Web of Science ®Google Scholar
• Groves M. J., Mustafa R. M.A. Measurement of the ‘spontaneity’ of self-emulsifiable oils. J. Pharm. Pharmac. 1974; 26: 671–681
   PubMed Web of Science ®Google Scholar
• Pouton C. W. Self-emulsifying drug delivery systems: assessment of their efficiency of emulsification. Int. J. Pharmaceut. 1985; 27: 335–348
   Web of Science ®Google Scholar
• Wakerly M. G., Pouton C. W., Meakin B. J., Morton F. S. Self-emulsification of vegetable oil-nonsurfactant mixtures: a proposed mechanism of action. Am. Chem. Soc. Symp. Ser. 1986; 311: 242–255
   Google Scholar
• Craig D. Q.M., Lievens H. S.R., Pitt K. G., Storey D. E. An investigation into the physico-chemical properties of self-emulsifying systems using low frequency dielectric spectroscopy, surface tension measurements and particle size analysis. Int. J. Pharmaceut. 1993; 96: 147–155
   Web of Science ®Google Scholar
• Craig D. Q., Barker S. A., Banning D., Booth S. W. Investigation into the mechanisms of self-emulsification using particle size analysis and low frequency dielectric spectroscopy. Int. J. Pharmaceut. 1995; 114: 103–110
   Web of Science ®Google Scholar
• Pouton C. W. Formulation of self-emulsifying drug delivery systems. Adv. Drug. Deliv. Rev. 1997; 25: 47–58
   Web of Science ®Google Scholar
• Gershanik T., Benita S. Positively charged self-emulsifying oil formulation for improving oral bioavailability of progersterone. Pharm. Dev. Technol. 1996; 1: 147–157
   PubMedGoogle Scholar
• Charman S. A., Charman W. N., Rogge M. C., Wilson T. D., Dutko F. J., Pouton C. W. Self-emulsifying drug delivery systems: formulation and biopharmaceutical evaluation of an investigational lipophilic compound. Pharm. Res. 1992; 9: 87–93
   PubMed Web of Science ®Google Scholar
• Lin J. H., Chen I., Lievens H. The effect of dosage forms on the oral absorption of L-365,260, a potent CCKB receptor antagonist in dogs. Pharm. Res. 1991; 8: S-272
   Google Scholar
• Shah N. H., Carvajal M. T., Patel C. I., Infeld M. H., Malick A. W. Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int. J. Pharmaceut. 1994; 106: 15–23
   Web of Science ®Google Scholar
• Kinget R., De Greef H. Absorption characteristics of novel 8-MOP semi-solid-lipid-matrix formulations: in vitro–in vivo correlation. Int. J. Pharmaceut. 1994; 110: 65–73
   Google Scholar
• Kelm G. R., Penafiel J. V., Deibel R. M., Kinnett G. O., Meredith M. P. The relative absorption of tebufalone from self-emulsifying solutions in the beagle dog. Pharm. Res. 1993; 10: S211
   Google Scholar
• Matuszewska B., Hettrick L., Bondi J. V., Storey D. E. Comparative bioavailability of L-683,453, a 5α-reductase inhibitor, from a self emulsifying drug delivery system in beagle dogs. Int. J. Pharm. 1996; 136: 147–154
   Google Scholar
• Gumkowski M. J., Fournier L. A., Tierney N. K., Curatolo W. J. Improved bioavailability through use of soft gelatin formulations of terlakiren, a tripeptide renin inhibitor. Pharm. Res. 1994; 11: S286
   Google Scholar
• Malcolmson C., Satra C., Kantaria S., Sidhu A., Lawrence M. J. Effect of oil on the level of solubilisation of testosterone propionate into non-ionic oil-in-water microemulsions. J. Pharm. Sci. 1988; 87: 109–116
   Google Scholar
• Malcolmson C., Lawrence M. J. Comparison of the incorporation of model steroids into non-ionic micellar and microemulsion systems. J. Pharm. Pharmacol. 1993; 45: 141–143
   PubMed Web of Science ®Google Scholar
• Sarciaux J. M., Acar L., Sado P. A. Using microemulsion formulations for oral drug delivery of therapeutic peptides. Int. J. Pharm. 1995; 120: 127–136
   Web of Science ®Google Scholar
• Constantinides P. P. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm. Res. 1995; 12: 1561–1572
   PubMed Web of Science ®Google Scholar
• New R. R.C., Kirby C. J. Solubilisation of hydrophilic drugs in oily formulations. Adv. Drug Deliv. Rev. 1997; 25: 59–69
   Web of Science ®Google Scholar
• Constantinides P. P., Scalart J. P. Formulation and physical characterisation of water-in-oil microemulsions containing long- versus medium chain glycerides. Int. J. Pharm. 1997; 158: 57–68
   Web of Science ®Google Scholar
• Reymond J., Sucker H. in vitro model for ciclosporin intestinal absorption in lipid vehicles. Pharm. Res. 1988; 5: 673–676
   PubMed Web of Science ®Google Scholar
• Reymond J., Sucker H., Vonderscher J. In vivo model for ciclosporin intestinal absorption in lipid vehicles. Pharm. Res. 1988; 5: 677–679
   PubMed Web of Science ®Google Scholar
• Behrens D., Fricker R., Bodoky A., Drewe J., Harder F., Heberer M. Comparison of cyclosporin A absorption from LCT and MCT solutions following intrajejunal administration in conscious dogs. J. Pharm. Sci. 1996; 85: 666–668
   PubMed Web of Science ®Google Scholar
• Beveridge T., Gratwohl A., Michot F., Niederberger W., Nuesch E., Nussbaumer K., Schaub P., Speck B. Cyclosporin A: pharmacokinetics after a single dose in man and serum levels after multiple dosing in recipients of allogenic bone marrow grafts. Curr. Ther. Res. 1981; 30: 5–18
   Web of Science ®Google Scholar
• Frey F. J., Horber F. F., Frey B. M. Trough levels and concentration time curves of cyclosporin in patients undergoing renal transplantation. Clin. Pharmac. Ther. 1988; 43: 55–62
   PubMed Web of Science ®Google Scholar
• Ptachcinski R., Venkataramanan R., Burckart G. J. Clinical pharmacokinetics of cyclosporin. Clinical Pharmacokin. 1986; 11: 107–132
   Google Scholar
• Ptachcinski R. J., Venkataramanan R., Rosenthal J. T., Burckart G. J., Taylor R. J., Hakala T. R. The effect of food on cyclospocrin absorption. Transplantation 1985; 40: 174–176
   PubMed Web of Science ®Google Scholar
• Gupta S. K., Benet L. Z. High fat meals increase the clearance of cyclosporine. Pharm. Res. 1990; 7: 46–48
   PubMed Web of Science ®Google Scholar
• Tarr B. D., Yalkowsky S. H. Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm. Res. 1989; 6: 40–43
   PubMed Web of Science ®Google Scholar
• Ritschel W. A. Microemulsions for improved peptide absorption from the gastrointestinal tract. Meth. Find. Exp. Clin. Pharmacol. 1991; 13: 205–220
   PubMed Web of Science ®Google Scholar
• Ritschel W. A., Adolf S., Ritschel G. B., Schroeder T. Improvement of peroral absorption of cyclosporine A by microemulsions. Meth. Find. Exp. Clin. Pharmacol. 1990; 12: 127–134
   PubMedGoogle Scholar
• Gao Z. G., Choi H. G., Shin H. J., Park K. M., Lim S. J., Hwang K. J., Kim C. K. Physicochemical characterisation and evaluation of a microemulsion system for oral delivery of cyclosporin A. Int. J. Pharmaceut. 1998; 161: 75–86
   Web of Science ®Google Scholar
• Drewe J., Meier R., Vonderscher J., Kiss D., Posanski U., Kissel T., Gyr K. Enhancement of the oral absorption of cyclosporin in man. Br. J. Clin. Pharmacol. 1992; 34: 60–64
   PubMed Web of Science ®Google Scholar
• Bojrup M., Qi Z., Bjorkman S., Ostraat O., Landin B., Ljusberg-Wahren H., Ekberg H. Bioavailability of cyclosporine in rats after intragastric administration: a comparitive study of the L2 phase and two other lipid-based vehicles. Transplant. Immunol. 1996; 4: 313–317
   PubMedGoogle Scholar
• Mueller E. A., Kovarik J. M., van Bree J. B., Tetzloff W., Grevel J., Kutz K. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm. Res. 1994; 11: 301–304
   PubMed Web of Science ®Google Scholar
• Kovarik J. M., Mueller E. A., van Bree J. B., Tetzloff W., Kutz K. Reduced inter and intraindividual variability in cyclosporine pharmacokinetics form a microemulsion formulation. J. Pharm. Sci. 1994; 83: 444–446
   PubMed Web of Science ®Google Scholar
• Trull A. K., Tan K. K.C., Tan L., Alexander G. J.M., Jamieson N. J. Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion. Br. J. Clin. Pharmacal. 1995; 39: 627–631
   PubMed Web of Science ®Google Scholar
• Mueller E. A., Kovarik J. M., van Bree J. B., Grevel J., Lucker P. W., Kutz K. Influence of a fat rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm. Res. 1994; 11: 151–155
   PubMed Web of Science ®Google Scholar
• Milton K. A., Edwards G., Ward S. A., Orme M. L., Breckenridge A. M. Pharmacokinetics of halofantrine in man: effects of food and dose size. Br. J. Clin. Pharmacol. 1989; 28: 71–77
   PubMed Web of Science ®Google Scholar
• Humberstone A. J., Porter C. J.H., Charman W. N. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. J. Pharm. Sci. 1996; 85: 525–529
   PubMed Web of Science ®Google Scholar
• Khoo S.-M., Humberstone A. J., Porter C. J.H., Edwards G. A., Charman W. N. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int. J. Pharmaceut. 1998; 167: 155–164
   Web of Science ®Google Scholar
• Benet L. Z., Wu C.-Y., Hebert M. F., Wacher V. J. Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery. J. Cont. Rel. 1996; 39: 139–143
   Web of Science ®Google Scholar
• Wacher V. J., Salphati L., Benet L. Z. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev. 1996; 20: 99–112
   Web of Science ®Google Scholar
• Thummel K. E., Kunze K. L., Shen D. D. Enzyme-catalised processes of first pass hepatic and intestinal drug extraction. Adv. Drug Deliv. Rev. 1997; 27: 99–127
   PubMed Web of Science ®Google Scholar
• Thummel K. E., O'Shea D., Paine M. F., Shen D. D., Kunze K. L., Perkins J. D., Wilkinson G. R. Oral first pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 1996; 59: 491–502
   PubMed Web of Science ®Google Scholar
• Hebert M. F. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv. Drug. Del. Rev. 1997; 27: 201–214
   PubMed Web of Science ®Google Scholar
• Vickers A. E.M., Fischer V., Connors S., Fisher R. L., Baldeck J. P., Maurer G., Brendel K. Cyclosporin A metabolism in human liver, kidney and intestinal slices. Drug Metab. Dispos. 1992; 20: 802–809
   PubMed Web of Science ®Google Scholar
• Wu C.-Y., Benet L. Z., Hebert M. F., Gupta S. K., Rowland M., Gomez D. Y., Wacher V. J. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin. Pharmacol. Ther. 1995; 58: 492–497
   PubMed Web of Science ®Google Scholar
• Lampen A., Christians U., Guengerich F. P., Watkins P. B., Kolars J. C., Bader A., Gonschior A.-K., Dralle H., Hackbarth I., Sewing K. F. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab. Dispos. 1995; 23: 1315–1324
   PubMed Web of Science ®Google Scholar
• Watkins P. B. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev. 1997; 27: 161–170
   PubMed Web of Science ®Google Scholar
• Fitzsimmons M. E., Collins J. M. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small intestinal cytochrome P4503A4. Drug Metab. Dispos. 1997; 25: 256–266
   PubMed Web of Science ®Google Scholar
• Koudriakova T., Iatsimirskaia E., Tulebaev S., Spetie D., Utkin I., Mullet D., Thompson T., Vouros P., Gerber N. In vivo disposition and metabolism by liver and enterocyte microsomes of the antitumour drug rifabutin in rats. J. Pharmacol. Exp. Therap. 1996; 279: 1300–1309
   PubMed Web of Science ®Google Scholar
• Lown K. S., Mayo R., Blake D. S., Benet L. Z., Watkins P. B. Interpatient variation in intestinal Pgp expression contributes to variable oral kinetics of cyclosporin A. Clin. Pharmacol. Ther. 1997; 62: 1–13
   PubMed Web of Science ®Google Scholar
• Hunter J., Jepson M. A., Tsuruo T., Simmons N. L., Hirst B. H. Functional expression of p-glycoprotein in apical membranes of human intestinal Caco-2 cell layers: kinetics of vinblastine secretion and interaction with modulators. J. Biol. Chem. 1993; 268: 14991–14997
   PubMed Web of Science ®Google Scholar
• Saitoh H., Aungst B. J. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across the rat intestine. Pharm. Res. 1995; 12: 1304–1310
   PubMed Web of Science ®Google Scholar
• Karlsson J., Kuo S. M., Ziemniak J., Artusson P. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including p-glycoprotein. Br. J. Pharm. 1993; 110: 1009–1016
   PubMed Web of Science ®Google Scholar
• Leu B. L., Huang J. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother. Pharmacol. 1995; 35: 432–436
   PubMed Web of Science ®Google Scholar
• Wacher V. J., Wu C.-Y., Benet L. Z. Overlapping substrate specificities and tissue distribution of Cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog 1995; 13: 129–134
   PubMed Web of Science ®Google Scholar
• Benet L. Z., Wacher V. J., Bener R. M. Use of essential oils to increase bioavailability of oral pharmaceutical compounds. United States Patent No 5,665,386, Sep 9, 1997
   Google Scholar
• Nerurkar M. M., Burton P. S., Borchardt R. T. The use of surfactant to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarised efflux system. Pharm. Res. 1996; 13: 528–534
   PubMed Web of Science ®Google Scholar
• Choc M. G., Robinson W. T. Gastrointestinal variables and water insoluble compounds in normal and disease states. Presentation to the AAPS/CRS/FDA workshop on scientific foundation and applications for the biopharmaceutics classification and in vitro–in vivo correlations, Arlington, VA, April, 14–161997
   Google Scholar
• Porter C. J.H., Charman S. A., Charman W. N. Lymphatic transport of halofantrine in the triple-cannulated anaesthetized rat model: effect of lipid vehicle dispersion. J.Pharm. Sci. 1996; 85: 351–356
   PubMed Web of Science ®Google Scholar
• Porter C. J.H., Charman S. A., Charman W. N. Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion. J. Pharm. Sci. 1996; 85: 357–361
   PubMed Web of Science ®Google Scholar
• Pantaleo G., Graziosi C., Butini L., Pizzo P. A., Schnittman S. M., Kotler D. P., Fauci A. S. Lymphoid organs as major reservoirs for human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 1991; 88: 9838–9842
   PubMed Web of Science ®Google Scholar
• Pantaleo G., Graziosi C., Demarest J. F., Butini L., Montroni M., Fox C. H., Orenstein J. M., Kotler D. P., Fauci A. S. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362: 355–358
   PubMed Web of Science ®Google Scholar
• Casley-Smith J. R. The fine structure and functioning of tissue channels and lymphatics. Lymphology 1980; 12: 177–183
   Google Scholar
• Casley-Smith J. R. Are the initial lymphatics normally pulled open by the anchoring filaments?. Lymphology 1980; 13: 120–129
   PubMedGoogle Scholar
• Yang V. V., O'Morchoe P. J., O'Morchoe C. C. Transport of protein across lymphatic endothelium in the rat kidney. Microvasc. Res. 1981; 21: 75–91
   PubMedGoogle Scholar
• O'Morchoe P. J., Yang V. V., O'Morchoe C. C. Lymphatic transport during volume expansion. Microvasc. Res. 1980; 20: 275–294
   PubMedGoogle Scholar
• O'Morchoe C. C., Albertine K. H., O'Morchoe P. J. The rate of translymphatic endothelial fluid movement in the canine kidney. Microvasc. Res. 1982; 23: 180–187
   PubMedGoogle Scholar
• Porter C. J.H. Drug delivery to the lymphatic system. Crit. Rev. Drug Carrier Syst. 1997; 14: 333–393
   PubMed Web of Science ®Google Scholar
• Charman W. N., Stella V. J. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int. J. Pharmaceut 1986; 34: 174–178
   Google Scholar
• Kuksis A. Absorption of fat soluble vitamins. Fat Absorption, A. Kuksis. CRC Press, Boca Raton 1987; 2: 65–86
   Google Scholar
• Palin K. J., Wilson C. J. The effect of different oils on the absorption of probucol in the rat. J. Pharm. Pharmacol. 1984; 36: 641–643
   PubMed Web of Science ®Google Scholar
• Grimus R. C., Schuster I. The role of the lymphatic transport in the enteral absorption of naftifine by the rat. Xenobiotica 1984; 14: 287–294
   PubMed Web of Science ®Google Scholar
• Katayama K., Fujita T. Studies on lymphatic absorption of 1′, 2′-(3H)-Coenzyme Q10 in rats. Chem. Pharm. Bull. 1972; 20: 2585–2592
   PubMed Web of Science ®Google Scholar
• Ueda C. T., Lemaire M., Gsell G., Nussbaumer K. Intestinal lymphatic absorption of cyclosporin A following oral administration in an olive oil solution to rats. Biopharm. Drug Dispos. 1983; 4: 113–124
   PubMed Web of Science ®Google Scholar
• Sieber S. M. The lymphatic absorption of p,p-DDT and some structurally-related compounds in the rat. Pharmacology 1976; 14: 443–454
   PubMed Web of Science ®Google Scholar
• Charman W. N., Noguchi T., Stella V. J. An experimental system designed to study the in situ intestinal lymphatic transport of drugs in anaesthetized rats. Int. J. Pharmaceut. 1986; 33: 155–164
   Web of Science ®Google Scholar
• Charman W. N., Stella V. J. Effect of lipid class and lipid vehicle volume on the intestinal lymphatic transport of DDT. Int. J. Pharmaceut. 1986; 33: 165–172
   Web of Science ®Google Scholar
• Sieber S. M., Cohn V. H., Wynn W. T. The entry of foreign compounds into the thoracic duct lymph of the rat. Xenobiotica 1974; 4: 265–284
   PubMed Web of Science ®Google Scholar
• Laher J. M., Rigler M. W., Vetter R. D., Barrowman J. A., Patton J. S. Similar bioavailability and lymphatic transport of benzo(a)pyrene when administered to rats in different amounts of dietary fat. J. Lipid. Res. 1984; 25: 1337–1342
   PubMed Web of Science ®Google Scholar
• Busbee D. L., Yoo J.-S. H., Norman J. O., Joe C. O. Polychlorinated biphenyl uptake and transport by lymph and plasma components. Proc. Soc. Exp. Biol. Med. 1985; 179: 116–122
   PubMed Web of Science ®Google Scholar
• Hauss D. J., Mehta S., Radebaugh G. W. Targeted lymphatic transport and modified systemic distribution of CI-976, a lipophilic lipid-regulator drug, via a formulation approach. Int. J. Pharmaceut. 1994; 108: 85–93
   Google Scholar
• Nankervis R., Davis S. S., Day N. H., Shaw P. N. Intestinal lymphatic transport of three retinoids in the rat after oral administration: effect of lipophilicity and lipid vehicle. Int. J. Pharmaceut. 1996; 130: 57–64
   Web of Science ®Google Scholar
• Kwei G. Y., Novak L. B., Hettrick L. H., Reiss E. R., Fong E. K., Olah T. V., Loper A. E. Lymphatic uptake of MK-386, a sterol 5α-reductase inhibitor, from aqueous and lipid formulations. Int. J. Pharm. 1998; 164: 37–44
   Google Scholar
• Takada K., Yoshimura H., Yoshikawa H., Muranishi S., Yasumura T., Oka S. Enhanced selective lymphatic delivery of cyclosporin A by solubilisers and intensified immunosuppressive activity against mice skin allograft. Pharm. Res. 1986; 3: 48–51
   PubMedGoogle Scholar
• Myers R., Stella V. J. Factors affecting the lymphatic transport of penclomedine (NSC-338720), a lipophilic cytotoxic drug: comparison to DDT and hexachlorobenzene. Int. J. Pharm. 1992; 80: 51–62
   Google Scholar
• Charman W. N., Porter C. J.H. Lipophilic prodrugs designed for intestinal lymphatic transport. Adv. Drug Deliv. Rev. 1996; 19: 149–169
   Web of Science ®Google Scholar
• Stella V. J., Pochopin N. L. Lipophilic prodrugs and the promotion of intestinal lymphatic drug transport. Lymphatic Transport of Drugs, W. N. Charman, V. J. Stella. CRC Press, Boca Raton 1992; 181–210
   Google Scholar
• Nishigaki R., Awazu S., Hanano M., Fuwa T. The effect of dosage form on absorption of vitamin A into lymph. Chem. Pharm. Bull. 1976; 24: 3207–3211
   PubMedGoogle Scholar
• Kuksis A. Effect of dietary fat on formation and secretion of chylomicrons and other lymph lipoproteins. Fat Absorption, A. Kuksis. Chap. 6, CRC Press, Boca Raton 1987; 2
   Google Scholar
• Blomhoff R., Helgerud P., Dueland S., Berg T., Pederson J. I., Norum K. R., Drevon C. A. Lymphatic absorption and transport of retinol and vitamin D-3 from rat intestine—evidence for different pathways. Biochim. Biophys. Acta 1984; 772: 109–116
   PubMedGoogle Scholar
• Vost A., Maclean A. Hydrocarbon transport in chylomicrons and high density lipoproteins in rat. Lipids 1984; 19: 423–435
   PubMed Web of Science ®Google Scholar
• Ichihashi T., Kinoshita H., Takagishi Y., Yamada H. Effect of oily vehicles on absorption of mepitiostane by the lymphatic system in rats. J. Pharm. Pharmacol. 1992; 44: 560–564
   PubMed Web of Science ®Google Scholar
• Geigy Scientific Tables. 8th Ed., Ciga-Geigy Ltd, BasleSwitzerland 1984
   Google Scholar
• Naito H. K. Disorders of lipid metabolism. Clinical Chemistry Theory Analysis and Correlation, L. A. Kaplan, A. J. Pesce. Mosby, St. Louis, Missouri 1989; 454–483
   Google Scholar
• Mayes P. A. Lipid transport and storage. Harper's Biochemistry, R. K. Murray, D. K. Granner, P. A. Mayes, V. W. Rodwell. Prentice Hall, New Jersey 1996; 254–269
   Google Scholar
• Urien S. Interaction of drugs with human plasma lipoproteins. Proceedings of the Symposium on Protein Binding and Drug Transport, J. P. Tillement, E. Lindenlaub. F. K. Schattauer Verlag, Stuttgart-New York 1986; 63–75
   Google Scholar
• Wasan K. W., Cassidy S. M. Role of plasma lipoprotiens in modifying the biological activity of hydrophobic drugs. J. Pharm. Sci. 1998; 87: 411–424
   PubMed Web of Science ®Google Scholar
• Shu H. P., Nichols A. V. Uptake of lipophilic carcinogens by plasma lipoproteins. Structure activity studies. Biochim. Biophys. Acta 1981; 665: 376–384
   PubMed Web of Science ®Google Scholar
• Urien S., Albengres E., Comte A., Kiechel J. R., Tillement J. P. Plasma protein binding and erythrocyte partitioning of nicardipine in vitro. J. Cardiovasc. Pharmacol. 1985; 7: 891–898
   PubMedGoogle Scholar
• Glasson S., Zini R., D'Athis P., Tillement J. P., Boissier J. R. The distribution of bound propranolol between the different human serum proteins. Mol. Pharmacol. 1980; 17: 187–191
   PubMedGoogle Scholar
• Chassany O., Urien S., Claudepierre P., Bastian G., Tillement J. P. Binding of anthracycline derivatives to human serum lipoproteins. Anticancer Res. 1994; 14: 2353–2355
   PubMedGoogle Scholar
• Bard J. M., Urien S., Fruchart J.-C., Tillement J.-P. Location of probucol in lipoproteins inferred from compositional analysis of lipoprotein particles. An in-vitro study. J. Pharm. Pharmacol. 1994; 46: 797–800
   PubMedGoogle Scholar
• Urien S., Albengres E., Comte A., Kiechel J., Tillement J. P. Plasma protein binding and erythrocyte partitioning of nicardipine in vitro. J. Cardio. Pharmacol. 1985; 7: 891–898
   PubMedGoogle Scholar
• Urien S., Zini R., Lemaire M., Tillement J. P. Assessment of cyclosporine A interactions with human plasma lipoproteins in vitro and In vivo in the rat. J. Pharm. Exp. Ther. 1990; 253: 305–309
   PubMedGoogle Scholar
• Wasan K. M., Pritchard P. H., Ramaswamy M., Wong W., Donnachie E. M., Brunner L. J. Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine. Pharm. Res. 1997; 4: 1613–l620
   Google Scholar
• Urien S., Claudepierre P., Meyer J., Brandt R., Tillement J. P. Comparative binding of etretinate and acitretin to plasma proteins and erythrocytes. Biochem. Pharmacol. 1992; 44: 1891–1893
   PubMedGoogle Scholar
• Simon N., Dailly E., Jolliet P., Tillement J.-P., Urien S. pH dependent binding of ligands to serum lipoproteins. Pharm. Res. 1997; 14: 527–532
   PubMedGoogle Scholar
• Glasson S., Zini R., Tillement J.-P. Multiple human serum binding of two thienpyridinic derivatives, ticlopidine and PCR 2362, and their distribution between HSA, a-acid glycoprotein and lipoproteins. Biochem. Pharmacol. 1982; 31: 831–135
   PubMed Web of Science ®Google Scholar
• Sgoutas D., MacMahon W., Love A., Jerunika I. Interaction of cyclosporin A with human lipoproteins. J. Pharm. Pharmacol. 1986; 38: 583–588
   PubMedGoogle Scholar
• Verrill H. L., Girgis R. E., Easterling R. E., Malhi B. S., Mueller W. F. Distribution of cyclosporine in blood of a renal transplant recipient with type V hyperlipoproteinemia. Clin. Chem. 1987; 33: 423–428
   PubMedGoogle Scholar
• Danon A., Chen Z. Binding of imipramine to plasma proteins: effect of hyperlipoproteinemia. Clin. Pharmacol. Ther. 1979; 25: 316–321
   PubMed Web of Science ®Google Scholar
• Eder H. A. The effect of diet on the transport of probucol in monkeys. Artery 1982; 10: 105–107
   PubMedGoogle Scholar
• Legg B., Gupta S. K., Rowland M. A model to account for the variation in cyclosporin binding to plasma lipids in transplant patients. Ther. Drug Monit. 1988; 10: 20–27
   PubMedGoogle Scholar
• Humberstone A. J., Porter C. J.H., Edwards G. A., Charman W. N. Association of halofantrine with post-prandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. J. Pharm. Sci. 1998; 87: 936–942
   PubMed Web of Science ®Google Scholar
• Gupta S. K., Benet L. Z. High fat meals increase the clearance of cyclosporin. Pharm. Res. 1990; 7: 46–48
   PubMed Web of Science ®Google Scholar
• Brajtberg J., Elberg S., Bolard J., Kobayashi G. S., Levy R. A., Ostlund R. E., Jr., Schlessinger D., Medoff G. Interaction of plasma proteins and lipoproteins with amphotericin B. J. Infect. Dis. 1984; 149: 986–997
   PubMedGoogle Scholar
• Wasan K. M., Vadiei K., Lopez-Berenstein G., Luke D. R. Pharmacokinetics, tissue distribution and toxicity of free and liposomal amphotericin B in diabetic rats. J. Infect. Dis. 1990; 161: 562–566
   PubMed Web of Science ®Google Scholar
• Lopez-Berenstein G. Liposomes as carriers of antifungal drugs. Ann. N.Y. Acad. Sci. 1988; 544: 590–597
   PubMedGoogle Scholar
• Pontani D. R., Sun D., Brown J. W., Shahied S. I., Plescia O. J., Schaffner C. P., Lopez-Berestein G., Sarin P. S. Inhibition of HIV replication by liposomal-encapsulated amphotercin B. Antiviral Res. 1989; 11: 119–125
   PubMed Web of Science ®Google Scholar
• Chabot G. G., Pazdur R., Valeriote F. A., Baker L. H. Pharmacokinetics and toxicity of a continuous infusion of amphotericin B in cancer patients. J. Pharm. Sci. 1989; 78: 307–310
   PubMed Web of Science ®Google Scholar
• Wasan K. M., Conklin J. S. Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis. Antimicrob. Agents Chemother. 1996; 40: 1806–1810
   PubMedGoogle Scholar
• Koldin M. H., Kobayashi G. S., Brajtburg J., Medoff G. Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity to rabbits. Antimicrob. Agents Chemother. 1985; 28: 144–145
   PubMed Web of Science ®Google Scholar
• Chavanet P., Joly V., Rigaud D., Bolard J., Carbon C., Yeni P. Influence of diet on experimental toxicity of amphotericin B deoxycholate. Antimicrob. Agents Chemother. 1994; 38: 963–968
   PubMed Web of Science ®Google Scholar
• Souza L. C., Maranhao R. C., Schrier S., Campa A. in vitro and In vivo studies of the decrease of amphotericin B toxicity upon association with a triglyceride rich emulsion. J. Antimicrob. Agents 1993; 32: 123–132
   Google Scholar
• Lemaire M., Tillement J.-P. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin in the blood. J. Pharm. Pharmacol. 1982; 34: 715–718
   PubMed Web of Science ®Google Scholar
• Lithell H., Odlind B., Selinus I., Lindberg A., Lindstrom B., Frodin L. Is the plasma lipoprotein pattern of importance for treatment with cyclosporine? Transplant. Proc. 1986; 18: 50–51
   Google Scholar
• De Kippel N., Sennesael J., Lamote J., Ebinger G., Keyser J. Cyclosporine leukoencephalopathy induced by intravenous lipid solution. Lancet 1992; 339: 1114–1115
   Google Scholar
• Nemunaitis J., Deeg H. J., Yee G. C. High cyclosporin levels after bone marrow transplantation associated with hypertriglyceridemia. Lancet 1986; 2: 744–745
   PubMedGoogle Scholar
• Amadottir M., Thysell H., Nilsson-Ehle P. Lipoprotein levels and post heparin lipase activities in kidney transplant recipients: ciclosporin-versus nonciclosporin-treated patients. Am. J. Kidney Dis. 1991; 17: 700–717
   PubMedGoogle Scholar
• Gardier A. M., Mathe D., Guedeney X., Barre J., Benvenutti C., Navarro N., Vernillet J., Loisance D., Cachera J. P., Jacotot B., Tillement J.-P. Effects of plasma lipid-levels on blood distribution and pharmacokinetics of cyclosporin A. Ther. Drug Monit. 1993; 15: 274–280
   PubMed Web of Science ®Google Scholar
• Lemaire M., Partridge W. M., Chaudhuri G. Influences of blood components on the tissue uptake indices of cyclosporin in rats. J. Pharmacol. Exp. Ther. 1988; 244: 740–743
   PubMedGoogle Scholar
• Partridge W. M. Carrier mediated transport of thyroid hormones through the rat blood brain barrier. Primary role of albumin bound hormone. J. Clin. Invest. 1979; 64: 145–154
   PubMedGoogle Scholar